SBT6050's TLR8 agonist payload targets the HER2-directed antibody payload. SBT6050 is designed to directly activate myeloid cells (e.g., macrophages, dendritic cells, myeloid-derived suppressor cells [MDSCs]) and secondarily activate natural killer (NK) and T cells in HER2-expressing tumors (Fig 2a and 2c).

**Conclusion**
- SBT6050 demonstrated a manageable safety profile with consistent anti-tumor activity across the dose range studied in patients with advanced HER2-expressing or amplified solid tumors.
- The preliminary safety profile supports evaluation of SBT6050 in combination with other HER2-directed agents such as trastuzumab deruxtecan and trastuzumab-tucatinib.

**Acknowledgment**
- Authors would like to thank and acknowledge the participating patients and their families as well as our research staff.
- This study is sponsored by Silverbird Therapeutics, Inc.
- The presenting author (S.J.K.) has no financial disclosures to report.